A Study of Continuous Oral Dosing of a Novel Antiandrogen MDV3100, in Castration-Resistant Bone Metastatic Prostate Cancer Patients Evaluating the Tumor Micro-Environment.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2014
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Medivation
- 07 Jun 2017 Biomarkers information updated
- 30 Jan 2014 According to ClinicalTrials.gov record study status changed from active, no longer recruiting to completed.
- 21 Jan 2014 New source identified and integrated (M.D. Anderson Cancer Center 2009-0886).